These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 10568615)

  • 41. Invited commentary: The scientific basis for stopping polio immunization.
    Hull HF; Aylward RB
    Am J Epidemiol; 1999 Nov; 150(10):1022-5. PubMed ID: 10568616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Intense campaign for vaccination with the oral polio vaccine: what are the repercussions on the enterovirus world?].
    Delpeyroux F; Guillot S; Szendröi A; Balanant J; Caro V; Cuervo N; Chevaliez S; Dahourou G; Crainic R
    Bull Soc Pathol Exot; 2000 Jul; 93(3):193-7. PubMed ID: 11030056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polio eradication--target 2000.
    Gomber S; Agarwal KN
    Indian J Pediatr; 1996; 63(4):477-83. PubMed ID: 10832468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gaps in our knowledge about transmission of vaccine-derived polioviruses.
    Fine PE
    Bull World Health Organ; 2000; 78(3):358-9. PubMed ID: 10812732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
    Badizadegan K; Kalkowska DA; Thompson KM
    Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
    Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
    J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The polio endgame.
    Minor P
    Hum Vaccin Immunother; 2014; 10(7):2106-8. PubMed ID: 25608050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress towards the global eradication of poliomyelitis.
    Hull HF; Ward NA
    World Health Stat Q; 1992; 45(2-3):280-4. PubMed ID: 1462662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
    Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular analysis and implications of neurovirulent circulating vaccine-derived poliovirus in Jamaica. A case report and review of literature.
    Jackson ST; Mullings AM; Booth TF; MacDonald L; Henry SO; Khan CA; McLaughlin PD
    West Indian Med J; 2008 Nov; 57(5):511-4. PubMed ID: 19565986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.
    Thompson KM; Duintjer Tebbens RJ
    Medscape J Med; 2008; 10(8):190. PubMed ID: 18924642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
    Immunization Systems Management Group of the Global Polio Eradication Initiative
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.
    Hampton LM; du Châtellier GM; Fournier-Caruana J; Ottosen A; Rubin J; Menning L; Farrell M; Shendale S; Patel M
    J Infect Dis; 2017 Jul; 216(suppl_1):S217-S225. PubMed ID: 28838193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospects for the eradication of infectious diseases.
    Stuart-Harris C
    Rev Infect Dis; 1984; 6(3):405-11. PubMed ID: 6377445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.